How has Revvity (RVTY) been performing? Here's a data-driven look at its financials, valuation, and shareholder returns.
Revenue Trend
Revvity's top line grew 3.7% to $2.86B in FY2025, compared to $2.76B in FY2024.
Over the past 4 years, revenue has declined sharply at 7.1% per year, from $3.83B to $2.86B. This is a significant erosion of the top line.
Revvity's $2.86B revenue base puts it in the smaller bracket among US health care companies.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | $2.86B | +3.7% |
| FY2024 | $2.76B | +0.2% |
| FY2023 | $2.75B | -16.9% |
| FY2022 | $3.31B | -13.5% |
| FY2021 | $3.83B | +1.2% |
See Revvity's complete revenue history below
Where Revvity's Revenue Comes From
Looking under the hood at Revvity's revenue mix for FY2025.
Product Revenue Mix (FY2025)
| Segment | Revenue | % of Total |
|---|---|---|
| Life Sciences | $1.43B | 50.1% |
| Diagnostics | $1.42B | 49.9% |
The biggest contributor, Life Sciences, makes up 50.1% of revenue and grew 14.1% over the prior year.
Revvity's Profit & Margins
Net income fell to $241.7M in FY2025, down 18.3% from $295.8M in FY2024.
Net profit margin compressed to 8.5% in FY2025 from 10.7% in FY2024.
FY2025 diluted EPS of $2.08 was down from the $2.41 reported in FY2024.
View Revvity's complete earnings and margin analysis
How Revvity Returns Cash to Shareholders
Revvity's FY2025 dividend came in at $0.29 per share, representing a 0.26% yield.
The dividend track record is notable: Revvity has maintained payouts for 10+ straight years.
With a 13.9% payout ratio, there's headroom for future dividend increases.
| Year | DPS | Payout Ratio |
|---|---|---|
| FY2025 | $0.29 | 13.9% |
| FY2024 | $0.28 | 11.6% |
| FY2023 | $0.28 | Net loss, payout ratio not meaningful |
| FY2022 | $0.28 | 6.2% |
| FY2021 | $0.28 | 3.4% |
Share repurchases are a significant part of the capital return story, Revvity has bought back $2.04B of stock in the last 11 years.
See how buybacks have impacted Revvity's share count over time
Balance Sheet Overview
| Metric | Value |
|---|---|
| Cash & Short-term Investments | $919.9M |
| Total Debt | $3.37B |
| Shareholders' Equity | $7.25B |
| Total Assets | $12.17B |
| Debt-to-Equity Ratio | 0.46x |
| Current Ratio | 1.68x |
| Interest Coverage | 3.9x |
| Free Cash Flow (TTM) | $508.3M |
Revvity has a debt-to-equity ratio of 0.46, a current ratio of 1.68, interest coverage of 3.9x in FY2025, which indicate a well-capitalized balance sheet with comfortable debt levels.
Balance sheet strength is evident: $919.9M in cash and equivalents, $3.37B in total debt, and a manageable 0.46x D/E ratio.
A 3.9x interest coverage ratio gives Revvity a moderate cushion above its debt service costs.
Strong free cash flow generation of $508.3M gives Revvity financial flexibility for capital allocation.
See the detailed financial health breakdown in the charts
As of FY2025, Revvity's workforce stood at 11,000, about $259.6K in revenue per employee.
See Revvity's full employee count history and revenue per employee
Valuation Check: Is Revvity Overpriced?
Let's put a fair value on Revvity using three independent valuation approaches.
Revvity shares are currently trading at $115.22.
The P/E Ratio approach puts Revvity's intrinsic value at $57, a 102.0% downside from the current market price.
We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | $57 | 102.0% downside to fair value |
| DCF | Upgrade | Upgrade |
| EPS Growth | Upgrade | Upgrade |
Key Takeaways
What should investors take away from Revvity's (RVTY) latest numbers? Here's the summary.
Revenue of $2.86B in FY2025, up 3.7% year-over-year.
Long-term revenue has been contracting at 7.1% annually over 4 years.
The company is profitable, with a net margin of 8.5% and net income of $241.7M.
Returned $853.6M to shareholders in FY2025 through dividends and/or buybacks.
Conservative balance sheet with a D/E ratio of 0.46x.
The P/E Ratio model implies 102.0% downside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion. Sign up to see the full analysis.
Scroll down for interactive charts covering Revvity's full financial history and valuation models.